Technology area: Biotechnology & Pharmaceuticals
27 pending office actions • 21 art units • 27 examiners • 0 of 27 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
The Children's Medical Center Corporation has 25 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 25 examiners and 19 art units, demonstrating a widely distributed prosecution docket across both examiner assignments and examination units. No examiner accounts for more than the recorded busiest-examiner workload, so the portfolio is not organized around a dominant examination relationship.
SAMALA, JAGADISHWAR RAO handles 1 pending matter and is the busiest examiner. The broad spread requires matter-level prosecution planning, with response positions tailored to individual records rather than applied uniformly. The art-unit distribution also suggests that claim scope, prior-art analysis, and evidentiary needs may differ across applications.
Counsel can still benefit from coordinated technical narratives, disclosure review, and tracking of recurring objections. Shared strategies should function as a framework, while amendments and interview plans remain responsive to each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (11%) |
| §103 only | 4 (15%) |
| §112 only | 2 (7%) |
| Double-patenting + other | 3 (11%) |
| Multi-statute (no §101) | 15 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.7% |
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| GEIGER, RACHAEL L | 1 | 82.3% | +18.3% |
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| GANESAN, SUBA | 1 | 73.8% | +13.4% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | MCLEOD, AFRICA MHAIRIE | 89d overdue |
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 45d overdue |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HUTTER, GILLIAN A | 1d overdue |
| 18320921 | SURGICAL REPAIR SIMULATION DEVICES | MCCLELLAN, JAMES S | 21d |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 54d |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18884967 | USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS | SAMALA, JAGADISHWAR RAO | — |
| 18720551 | ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 45d overdue |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 54d |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18884967 | USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS | SAMALA, JAGADISHWAR RAO | — |
| 18835427 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | HIBBERT, CATHERINE S | — |
| 18720551 | ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION | SHIN, DANA H | — |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | KASSA, TIGABU | — |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1635 | 2 |
| 1653 | 2 |
| 1634 | 2 |
| 3715 | 2 |
| 1618 | 1 |
| 1658 | 1 |
| 1619 | 1 |
| 3771 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18884967 | USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS | SAMALA, JAGADISHWAR RAO | 1618 | §102§103 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18835427 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | HIBBERT, CATHERINE S | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18720551 | ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION | SHIN, DANA H | 1635 | §102§103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | KASSA, TIGABU | 1619 | §102§103 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18703100 | SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS | GEIGER, RACHAEL L | 3771 | §102§103 | Non-Final OA | 54d | Pending | Apr 19, 2024 |
| 18424292 | COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Final Rejection | 45d overdue | Pending | Jan 26, 2024 |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | AEDER, SEAN E | 1642 | §103 | Final Rejection | — | Pending | Dec 21, 2023 |
| 18520488 | COLLAGEN SCAFFOLDS | GANESAN, SUBA | 3774 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 61d | Pending | Oct 11, 2023 |
| 18549676 | METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | GABEL, GAILENE | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18236602 | SYSTEMS FOR ANALYZING PATTERNS IN ELECTRODERMAL ACTIVITY RECORDINGS OF PATIENTS TO PREDICT SEIZURE LIKELIHOOD AND METHODS OF USE THEREOF | GOMES, SRISTI DIVINA | 3791 | §101§103 | Final Rejection | — | Pending | Aug 22, 2023 |
| 18360505 | COMPOSITIONS AND METHODS FOR TREATING CEREBROSPINAL FLUID DISORDERS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18352730 | COMPOSITIONS AND METHODS FOR NEUROPROTECTION AND/OR NEUROREGENERATION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18341584 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT | ANDERSON, JAMES D | 1629 | §112 | Non-Final OA | 171d overdue | Pending | Jun 26, 2023 |
| 18206830 | METHOD FOR TREATING CANCER | REGLAS, GEORGIANA C | 1651 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18320927 | SURGICAL REPAIR SIMULATION DEVICES | HULL, JAMES B | 3715 | §103 | Final Rejection | 28d overdue | Pending | May 19, 2023 |
| 18320921 | SURGICAL REPAIR SIMULATION DEVICES | MCCLELLAN, JAMES S | 3715 | §102§103 | Non-Final OA | 21d | Pending | May 19, 2023 |
| 18016190 | TARGETING ZNF410 FOR FETAL HEMOGLOBIN INDUCTION IN BETAHEMOGLOBINOPATHIES | VANHORN, ABIGAIL LOUISE | 1636 | §112DP | Non-Final OA | — | Pending | Jan 13, 2023 |
| 18002633 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | KIM, TAEYOON | 1631 | §103DP | Final Rejection | — | Pending | Dec 20, 2022 |
| 18011089 | COMPOSITIONS AND METHODS FOR REGULATING ENTEROENDOCRINE CELL DIFFERENTIATION AND USES THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Final Rejection | — | Pending | Dec 16, 2022 |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HUTTER, GILLIAN A | 1625 | §102§103 | Final Rejection | 1d overdue | Pending | Dec 09, 2022 |
| 18074107 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION | MARVICH, MARIA | 1634 | §112Other | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17921802 | COMPOSITIONS AND METHODS OF PROMOTING MYELINATION | TICHY, JENNIFER M.H. | 1653 | §103 | Final Rejection | — | Pending | Oct 27, 2022 |
| 17801238 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AN ALLERGY OR ANAPHYLAXIS | BUNNER, BRIDGET E | 1647 | §101§102§112 | Final Rejection | — | Pending | Aug 19, 2022 |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2022 |
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112Other | Final Rejection | 89d overdue | Pending | Apr 07, 2022 |
| 17764413 | BCL11A GUIDE AND BASE EDITOR DELIVERY | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Non-Final OA | 89d overdue | Pending | Mar 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Children's Medical Center Corporation has 27 pending office actions as of October 2026, spread across 21 art units and 27 examiners.
Jagadishwar Rao Samala has the most, with 1 of The Children's Medical Center Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
